ZL-1310 + atezolizumab

ZL-1310 + atezolizumab is an investigational combination therapy under study for the treatment of extensive-stage small cell lung cancer (ES-SCLC) and potentially other neuroendocrine tumors that express delta-like ligand 3 (DLL3)[3][7]. ZL-1310 is a first-in-class antibody-drug conjugate (ADC) composed of a humanized anti-DLL3 monoclonal antibody linked to a novel camptothecin derivative, engineered to selectively target DLL3, an antigen overexpressed in SCLC and other neuroendocrine cancers[7]. Atezolizumab (Tecentriq) is a fully humanized IgG1 monoclonal antibody immune checkpoint inhibitor that binds to programmed death-ligand 1 (PD-L1), blocking its interaction with PD-1 and B7.1 receptors, resulting in reactivation of T-cells and restoration of anti-tumor immune responses[2][7][6]. The combination aims to couple the direct cytotoxicity of the DLL3-targeted ADC with immune activation and reversal of tumor immunosuppression via PD-L1 blockade.

Brand names

Tecentriq

Other names

ZL-1310 + Tecentriq